Immune checkpoint blockade, or ICB, has transformed cancer treatment by releasing molecular brakes that restrain T cells. Drugs that block proteins such as PD-1, PD-L1 or CTLA-4 can restore the ability of T cells to recognize and attack malignant cells, producing long-lasting responses in some people with cancer. Yet the treatment does not work uniformly. Its success depends on a chain of events in which tumor antigens are captured, processed and displayed to T cells by antigen-presenting cells, particularly dendritic cells. Among these, conventional type 1 dendritic cells, known as cDC1s, have attracted intense attention because they are highly effective at cross-presenting tumor-derived proteins on major histocompatibility complex class I molecules, a process that activates tumor-killing CD8-positive T cells.

The new work examined whether cDC1s are absolutely required for ICB to eliminate a primary tumor. To do so, the researchers used mice carrying an immunogenic clone of Lewis lung carcinoma, or LLC, a transplantable mouse tumor model. They compared normal animals with genetically modified Batf3-deficient mice. The Batf3 transcription factor is necessary for the development of cDC1s, so Batf3-knockout animals lack this dendritic-cell subset. In normal mice, most animals rejected the LLC tumors after receiving ICB. Surprisingly, the treatment also triggered tumor rejection in 35.7 percent of the Batf3-deficient mice. The result indicates that, at least for this immunogenic LLC tumor, alternative antigen-presenting cells can support an initial antitumor response when cDC1s are absent.

That alternative route appears to involve XCR1-negative antigen-presenting cells. XCR1 is a chemokine receptor associated with cDC1s, making it a useful marker for distinguishing these cells from other antigen-presenting populations. After ICB, the researchers observed increased expression of costimulatory molecules on XCR1-negative APCs in both tumors and draining lymph nodes of Batf3-deficient mice. Costimulatory molecules such as CD40 and CD80 provide essential secondary signals during T-cell activation. Antigen recognition alone is often insufficient; without costimulation, T cells may become inactive or tolerant. The observed increase in CD40 and CD80 suggests that non-cDC1 APCs were not merely present but were being functionally activated in response to checkpoint therapy.

The researchers then investigated why the LLC model could provoke this backup immune pathway while another tumor model, the B16F10 melanoma, remained resistant to ICB. They collected conditioned culture media—the fluid containing molecules secreted by tumor cells—from LLC and B16F10 cultures and exposed bone-marrow-derived dendritic cells to it. Media from LLC cells stimulated both cDC1s and cDC2s, another conventional dendritic-cell subset, causing increased expression of CD40 and CD80. Media from ICB-resistant B16F10 cells did not produce the same effect. This experiment points to soluble factors released by the tumor microenvironment as potential drivers of dendritic-cell activation. The molecules were not identified in the study, but the contrast suggests that tumor cells can differ substantially in their ability to alert and organize immune responses.

To explore that difference at the molecular level, the team performed RNA sequencing on LLC and B16F10 tumor cells. The analysis showed that genes linked to antitumor immunity were more strongly expressed in LLC cells than in B16F10 cells. Such genes could influence how tumor antigens are released, how inflammatory signals are generated or how immune cells are recruited and activated. A tumor that produces the right combination of danger signals may effectively condition multiple APC populations, creating redundancy in the pathway leading to T-cell activation. By contrast, an immune-cold tumor such as B16F10 may fail at several points: it may present fewer recognizable antigens, release weaker activating signals or actively suppress the cells that would otherwise initiate immunity.

The most consequential finding emerged when the researchers tested immune memory. Mice that had become tumor-free after ICB were later exposed again to LLC tumors, a standard rechallenge experiment designed to determine whether the initial response created protective immunological memory. In Batf3-deficient animals that had rejected their primary tumors without cDC1 supplementation, the rechallenged tumors were not spontaneously eliminated. In other words, the mice could mount a successful first attack but did not retain a sufficiently powerful memory response to repel the same tumor a second time. This distinction is biologically important. Primary rejection can rely on a temporary or locally organized immune response, whereas durable memory requires the generation, survival and later reactivation of specialized T-cell populations, processes that depend on precise antigen presentation and coordination among immune cells.

The findings support a two-stage model of checkpoint immunotherapy. During the first stage, activated XCR1-negative APCs, including cDC2-like populations, may present tumor antigens and provide costimulation strong enough to initiate T-cell-mediated destruction. These cells could acquire tumor material in the tumor bed or draining lymph nodes, process it and present it to T cells through major histocompatibility complex molecules. Checkpoint blockade would then remove inhibitory signaling, allowing the newly activated T cells to expand and attack the cancer. During the second stage, however, cDC1s may be indispensable for shaping the quality and persistence of the response. Their specialized cross-presentation capacity could help sustain repeated T-cell stimulation, support the development of memory precursor cells and establish long-term surveillance against residual or returning tumor cells.

The work does not mean that cDC1s are unimportant in all cancers, nor does it show that patients lacking a direct equivalent of the mouse pathway would respond in the same way. The experiments used genetically modified mice and transplantable tumor models, and the percentage of Batf3-deficient animals rejecting LLC was substantially lower than the response seen in wild-type mice. The results instead highlight the complexity of immune responses within tumors and the danger of reducing immunotherapy to a single cellular mechanism. Future treatments may need to activate both cDC1-dependent and cDC1-independent pathways: one to generate a forceful initial attack and another to ensure that the immune system remembers what it has defeated. Identifying the soluble tumor-derived signals that activate alternative APCs could help explain why some cancers respond to ICB while others resist it, while strategies that restore or enhance cDC1 function could improve the durability of responses. The study’s central message is therefore both encouraging and cautionary: the immune system may find more than one way to destroy a tumor, but the route to lasting protection is narrower than the route to an initial victory.

In an illuminating study recently published in the prestigious journal Nature, researchers at the University of Michigan have uncovered a pivotal mechanism that dictates how tumors respond to immune checkpoint blockade. Central to this mechanism is a delicate regulatory balance between two closely related proteins, STAT3 and STAT5, which orchestrates the function of dendritic cells—the immune system’s critical generals. These dendritic cells patrol bodily tissues, continuously scouting for abnormal proteins and orchestrating T cell activation by presenting these tumor antigens. The University of Michigan team discovered that the ratio of STAT3 to STAT5 within dendritic cells profoundly influences their ability to mature and stimulate an effective T cell response against cancer.

Extensive analysis using RNA sequencing data from cancer patients revealed a striking correlation: patients who responded favorably to checkpoint inhibitor therapy demonstrated enhanced STAT5 activity coupled with suppressed STAT3 signaling. In contrast, elevated STAT3 levels undermined dendritic cell maturation and their capacity to activate T cells, thereby facilitating immune evasion by the tumor. Experimental models in mice further corroborated these findings, showing that STAT3 acts antagonistically to STAT5, hindering the immune system’s ability to mount a robust anti-tumor defense. This insight unravels a previously unappreciated molecular axis contributing to the pervasive problem of resistance against immune checkpoint inhibitors.

The discovery that STAT3 impairs dendritic cell function and thus immune activation is especially noteworthy given the historical context of STAT3 as a cancer target. While STAT3 has long been recognized for its role in promoting tumor growth and survival, it has been notoriously difficult to target pharmacologically—a challenge that has earned it the reputation of being “undruggable.” This limitation has stalled clinical progress for years, preventing the development of effective STAT3 inhibitors that could potentially overcome tumor immune resistance.

To circumvent this obstacle, the research team employed an innovative approach grounded in the cell’s own protein quality control systems. Rather than inhibiting STAT3’s activity directly, they designed molecules capable of recruiting the body’s intrinsic protein degradation machinery to selectively dismantle STAT3. Named SD-36 and SD-2301, these novel compounds effectively tagged STAT3 for destruction, reducing its abundance in dendritic cells. In doing so, they liberated STAT5-mediated signaling pathways, thereby promoting dendritic cell maturation and enhancing T cell activation within the tumor microenvironment.

The implications of this approach were profound. Treatment with these STAT3 degraders in cell culture and animal models not only bolstered antitumor immunity but also demonstrated efficacy in combating large, advanced tumors that were resistant to existing immune checkpoint therapies. This evidence suggests that targeting the STAT3-STAT5 axis via protein degradation mechanisms could serve as a versatile and powerful strategy to sensitize tumors to immunotherapy, addressing a critical unmet need in cancer treatment.

Moreover, the robustness of these findings across multiple tumor types—including skin, ovarian, breast, lung, and colon cancers—underscores the broad applicability of this novel therapeutic concept. Since STAT3 activation is a common feature across diverse malignancies, the development of STAT3-targeted degraders might herald a new era in immuno-oncology, one where refractory tumors can be rendered vulnerable to immune system attack.

The innovative nature of leveraging the body’s own proteolytic systems to strike at once “undruggable” targets represents a paradigm shift in drug discovery. By degrading rather than inhibiting proteins, researchers bypass traditional challenges associated with blocking protein function, opening new avenues for therapeutic intervention. This strategy aligns with the growing field of targeted protein degradation, which promises to expand the repertoire of treatable molecular targets beyond what conventional inhibitors can achieve.

Looking ahead, the University of Michigan researchers are preparing to transition their most promising STAT3 degraders into clinical trials. This move aims to evaluate the safety and efficacy of these molecules in human cancer patients, potentially transforming the standard of care for those who currently derive limited benefit from immunotherapy. If successful, these trials could validate a strategy that not only revitalizes the immune response but also overcomes a fundamental mechanism of cancer resistance.

Cancer immunotherapy has long been heralded as a breakthrough in oncology, yet the battle against tumor immune evasion continues to demand innovative solutions. The discovery and pharmacological targeting of the STAT3-STAT5 balance in dendritic cells offer a beacon of hope, demonstrating the intricate interplay within the immune system and revealing a vulnerability that can be exploited therapeutically. This research exemplifies how integrating molecular biology, immunology, and medicinal chemistry can unravel complex resistance mechanisms and translate them into effective clinical strategies.

Professor Weiping Zou, whose team spearheaded this research, emphasized the critical nature of understanding the underpinnings of immunotherapy resistance. By drawing parallels between the immune system and a military operation, Zou highlighted the fundamental roles of dendritic “generals” and T cell “soldiers” in coordinating an effective immune assault on cancer. Disrupting this coordination through STAT3 overactivation disrupts immune communication and blunts the attack on tumors, hence the importance of restoring this balance.

Simultaneously, Professor Shaomeng Wang’s expertise in pharmacology and internal medicine was instrumental in designing the STAT3 degraders, marking a fruitful convergence between basic research and drug development. Wang noted the longstanding challenge of targeting STAT3 and expressed optimism that these new molecules could finally unlock the therapeutic potential of this elusive protein.

This study not only contributes to the scientific community’s understanding of tumor immunology but also exemplifies the translational power of fundamental discoveries. By elucidating a key immune resistance mechanism and demonstrating a viable means to overcome it, the work sets the stage for next-generation immunotherapies that could benefit countless cancer patients worldwide.

As the field moves forward, these findings are expected to inspire further investigation into the regulatory networks controlling dendritic cell function and immune activation. The growing interest in protein degradation technologies will likely fuel the development of additional degraders targeting other pivotal immune and oncogenic proteins, broadening the therapeutic landscape beyond cancer.

In conclusion, the University of Michigan’s identification of the STAT3-STAT5 dynamic as a critical determinant of dendritic cell function and tumor immunity marks a milestone in cancer immunotherapy research. The innovative approach of targeting STAT3 for degradation constitutes a promising avenue to enhance responses to immune checkpoint inhibitors and tackle resistance, offering renewed hope that harnessing and directing the immune system’s intricate machinery can overcome even the most challenging cancers.

Subject of Research: Animals

Article Title: STAT5 and STAT3 Balance Shapes Dendritic Cell Function and Tumor Immunity

News Publication Date: 14-May-2025

Web References: https://www.nature.com/articles/s41586-025-09000-3

References: DOI 10.1038/s41586-025-09000-3

Keywords: Health and medicine